A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease.

Authors : Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart-Gebhart M, Vobecky N, Thuresson M, Flamen P
Year : 2014
Journal : Breast Cancer Res. Treat.
Volume : 145(2)
Pages : 411-8

Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.

Authors : Bozovic-Spasojevic I, Ameye L, Paesmans M, Larsimont D, Di Leo A, Dolci S, Piccart-Gebhart M, de Azambuja E, Loi S
Year : 2014
Journal : Breast
Volume : 23(4)
Pages : 473-81

Tumor infiltrating lymphocytes is prognostic and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

Authors : Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V, Desmedt C, Piccart-Gebhart M, Loibl S, Denkert C, Smyth MJ, Joensuu H, Sotiriou C
Year : 2014
Journal : Ann Oncol
Volume : 25(8)
Pages : 1544-50

Controversial Issues in Early Stage Breast Cancer: a Global Collaborative Survey, supported by the European Society for Medical Oncology (ESMO).

Authors : Zardavas D, Ades F, Spasojevic IB, Pugliano L, Capelan M, Paesmans M, de Azambuja E, Piccart-Gebhart M
Year : 2014
Journal : Ann Oncol
Volume : 25(8)
Pages : 1558-62

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC).

Authors : Awada A, Bondarenko IN, Bonneterre J, Nowara E, Ferrero JM, Bakshi AV, Wilke C, Piccart-Gebhart M
Year : 2014
Journal : Ann Oncol
Volume : 25(4)
Pages : 824-31

The landscape of medical oncology in Europe by 2020.

Authors : de Azambuja E, Ameye L, Paesmans M, Zielinski CC, Piccart-Gebhart M, Preusser M
Year : 2014
Journal : Ann Oncol
Volume : 25(2)
Pages : 525-8

Everolimus plus exemestane as first-line therapy in HR(+), HER2 (-) advanced breast cancer in BOLERO-2.

Authors : Beck JT, Hortobagyi GN, Campone M, Lebrun F, Deleu I, Rugo HS, Pistilli B, Masuda N, Hart L, Melichar B, Dakhil S, Geberth M, Nunzi M, Heng DY, Brechenmacher T, El-Hashimy M, Douma S, Ringeisen F, Piccart-Gebhart M
Year : 2014
Journal : Breast Cancer Res. Treat.
Volume : 143(3)
Pages : 459-67

Hurdles and delays in access to anti-cancer drugs in Europe.

Authors : Ades F, Zardavas D, Senterre C, de Azambuja E, Eniu A, Popescu R, Piccart-Gebhart M, Parent F
Year : 2014
Journal : Ecancermedicalscience
Volume : 8(null)
Pages : 482

An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: The trastuzumab case.

Authors : Ades F, Senterre C, Zardavas D, de Azambuja E, Popescu R, Parent F, Piccart-Gebhart M
Year : 2014
Journal : Eur. J. Cancer
Volume : 50(18)
Pages : 3089-97

Genomic grade adds prognostic value in invasive lobular carcinoma.

Authors : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : Ann Oncol
Volume : 24
Pages : 377-384

Genomic grade adds prognostic value in invasive lobular carcinoma.

Authors : Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Sandy H, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart-Gebhart M, Sotiriou C
Year : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 377-84

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.(epub nov 2013)

Authors : Awada A, Dumez H, Hendlisz A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart-Gebhart M, Schöffski P
Year : 2013
Journal : Invest New Drugs
Volume : 31(3)
Pages : 734-41

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

Authors : Goss PE, Smith IE, + collaborators (among others :, Piccart-Gebhart M, Finkelstein DM
Year : 2013
Journal : Lancet Oncol
Volume : 14(1)
Pages : 88-96

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

Authors : Kerklaan BM, Diéras V, Le Tourneau C, Mergui-Roelvink M, Huitema AD, Rosing H, Beijnen JH, Marreaud S, Govaerts AS, Piccart-Gebhart M, Schellens JH, Awada A
Year : 2013
Journal : Cancer Chemother Pharmacol
Volume : 71(1)
Pages : 53-62

Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study.

Authors : Azim HA, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, De Mattos-Arruda L, Pistilli B, Pinto A, Jensen MB, Cordoba O, de Azambuja E, Goldhirsch A, Piccart-Gebhart M, Peccatori FA
Year : 2013
Journal : J. Clin. Oncol.
Volume : 31(1)
Pages : 73-9

Pertuzumab: new hope for patients with HER2-positive breast cancer.

Authors : Capelan M, Pugliano L, de Azambuja E, Bozovic I, Saini KS, Sotiriou C, Loi S, Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(2)
Pages : 273-82

Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.

Authors : Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart-Gebhart M
Year : 2013
Journal : Eur. J. Cancer
Volume : 49(12)
Pages : 2621-32

Personalised cancer management: closer, but not here yet.

Authors : Piccart-Gebhart M
Year : 2013
Journal : Ann Oncol
Volume : 24(8)
Pages : 1951-5

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.

Authors : Yardley DA, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart-Gebhart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS
Year : 2013
Journal : Adv Ther
Volume : 30(10)
Pages : 870-84

Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy.

Authors : Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart-Gebhart M, Hortobagyi GN, Nunzi M, Heng DY, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA
Year : 2013
Journal : Curr Med Res Opin
Volume : 29(11)
Pages : 1463-73